Yu KS - Search Results

1

Pharmacokinetic profiles of ceftazidime after intravenous administration in patients undergoing automated peritoneal dialysis.

Kim K, Hwang YH, Ro H, Oh YK, Kim MG, Yu KS, Shin KH, Jang IJ, Shin SG, Ahn C, Oh KH. Kim K, et al. Among authors: yu ks. Antimicrob Agents Chemother. 2011 Jun;55(6):2523-7. doi: 10.1128/AAC.01543-10. Epub 2011 Mar 14. Antimicrob Agents Chemother. 2011. PMID: 21402833 Free PMC article.

2

Pharmacokinetic/pharmacodynamic evaluation of a novel potassium channel opener, SKP-450, in healthy volunteers.

Jang IJ, Yu KS, Shon JH, Bae KS, Cho JY, Yi SY, Shin SG, Ryu KH, Cho YB, Kim DK, Yoo SE. Jang IJ, et al. Among authors: yu ks. J Clin Pharmacol. 2000 Jul;40(7):752-61. doi: 10.1177/00912700022009512. J Clin Pharmacol. 2000. PMID: 10883417 Clinical Trial.

3

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.

Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, Jang IJ, Yi SY, Bae KS, Shin SG. Yu KS, et al. Clin Pharmacol Ther. 2001 Apr;69(4):266-73. doi: 10.1067/mcp.2001.114231. Clin Pharmacol Ther. 2001. PMID: 11309556 Clinical Trial.

4

Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin.

Yu KS, Cho JY, Shon JH, Bae KS, Yi SY, Lim HS, Jang IJ, Shin SG. Yu KS, et al. Clin Pharmacol Ther. 2001 Sep;70(3):228-36. doi: 10.1067/mcp.2001.117703. Clin Pharmacol Ther. 2001. PMID: 11557910 Clinical Trial.

5

Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.

Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Cho JY, et al. Among authors: yu ks. Br J Clin Pharmacol. 2002 Apr;53(4):393-7. doi: 10.1046/j.1365-2125.2002.01366.x. Br J Clin Pharmacol. 2002. PMID: 11966672 Free PMC article. Clinical Trial.

6

Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography.

Cho JY, Seo HB, Yu KS, Bae KS, Yi SY, Jang IJ, Shin SG. Cho JY, et al. Among authors: yu ks. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 25;784(1):25-31. doi: 10.1016/s1570-0232(02)00750-x. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12504179

7

Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urine.

Cho JY, Lim HS, Yu KS, Shim HJ, Jang IJ, Shin SG. Cho JY, et al. Among authors: yu ks. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):179-86. doi: 10.1016/s1570-0232(03)00565-8. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 14522022

8

Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.

Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS. Yu KS, et al. J Clin Pharmacol. 2004 Jan;44(1):73-82. doi: 10.1177/0091270003261321. J Clin Pharmacol. 2004. PMID: 14681344 Clinical Trial.

9

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG. Yu KS, et al. Clin Pharmacol Ther. 2004 Aug;76(2):104-12. doi: 10.1016/j.clpt.2004.03.009. Clin Pharmacol Ther. 2004. PMID: 15289787

10

Haplotype structure and allele frequencies of CYP2B6 in a Korean population.

Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, Shin SG, Jang IJ. Cho JY, et al. Among authors: yu ks. Drug Metab Dispos. 2004 Dec;32(12):1341-4. doi: 10.1124/dmd.104.001107. Epub 2004 Sep 21. Drug Metab Dispos. 2004. PMID: 15383491

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

421 results

Search Page

Filters